Ipamorelin + MOTS-c Stack: Complete Protocol, Dosing, and Mechanisms

What Is Ipamorelin and How Does It Work?

Ipamorelin is a synthetic pentapeptide that selectively stimulates pituitary growth hormone release by binding the ghrelin receptor (GHS-R1a) without meaningfully raising cortisol, prolactin, or ACTH at standard doses. That selectivity distinguishes it from older secretagogues like GHRP-6. A 2001 receptor-binding study confirmed ipamorelin's high GHS-R1a affinity and its clean endocrine profile relative to other GHRPs [1].

GH Pulse Physiology

The pituitary releases GH in discrete pulses, predominantly during slow-wave sleep. Ipamorelin amplifies pulse amplitude rather than creating a flat, pharmacological GH elevation. Physiologic pulsatility matters because continuous GH exposure downregulates receptors and may worsen insulin resistance over time [2].

Downstream IGF-1 Effects

After GH release, the liver produces IGF-1 (insulin-like growth factor 1). IGF-1 mediates most of the anabolic and lipolytic effects attributed to GH. In GH-deficient adults, IGF-1 levels below 100 ng/mL correlate with reduced lean mass, increased visceral fat, and impaired bone density [3]. Ipamorelin reliably raises IGF-1 within 4 to 8 weeks at 200 to 300 mcg/day in clinical observation, though formal dose-finding RCTs in healthy adults remain sparse.

Why Ipamorelin Over GHRP-6 or GHRP-2?

GHRP-6 produces significant cortisol and prolactin spikes alongside GH. GHRP-2 is more potent but similarly cortisol-raising. For practitioners seeking a cleaner GH stimulus with less hypothalamic-pituitary-adrenal axis interference, ipamorelin is the preferred starting point.

What Is MOTS-c and Why Does It Matter Metabolically?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA, not nuclear DNA. It was first characterized in 2015 by Lee et al. In Cell Metabolism, where intraperitoneal injection in mice at 15 mg/kg prevented high-fat-diet-induced obesity and improved insulin sensitivity without caloric restriction [4].

Mitochondrial Origin and AMPK Activation

MOTS-c translocates from mitochondria to the nucleus under metabolic stress. Once there, it activates AMPK (AMP-activated protein kinase) and suppresses the folate cycle, shifting one-carbon metabolism toward glucose utilization [4]. AMPK activation has downstream effects on GLUT4 translocation, fatty acid oxidation, and mTOR regulation. These are the same pathways targeted by metformin, which may explain why MOTS-c is sometimes described as a "mitochondrial signal" that mimics exercise biochemistry [5].

Human Aging Data

Circulating MOTS-c declines with age in humans. A 2019 cross-sectional study (N=143) found that plasma MOTS-c was significantly lower in older adults (mean age 75) compared with younger controls (mean age 36), and correlated inversely with insulin resistance as measured by HOMA-IR [6]. This age-related decline provides a physiologic rationale for exogenous supplementation in older individuals seeking to restore metabolic function.

Exercise Mimicry

Strenuous exercise acutely raises circulating MOTS-c in skeletal muscle. A 2019 study by Reynolds et al. Demonstrated that plasma MOTS-c rose approximately 1.5-fold after a single bout of high-intensity exercise and that baseline MOTS-c levels predicted insulin sensitivity better than fasting glucose alone [7]. The implication: exogenous MOTS-c may partly replicate the metabolic benefits of exercise at the cellular level.

Why Stack Ipamorelin with MOTS-c?

These two peptides act on separate but interconnected axes. Ipamorelin stimulates the GH-IGF-1 axis, promoting lean mass accrual, lipolysis, and tissue repair. MOTS-c targets mitochondrial efficiency and insulin sensitivity via AMPK. The combination addresses both anabolic signaling and the metabolic substrate utilization needed to make that anabolism efficient.

Mechanistic Complementarity

GH itself is mildly insulin-antagonizing. At supraphysiologic levels, GH raises fasting glucose and can impair glucose tolerance. A 2013 meta-analysis of GH replacement in adults (N=548 across 14 trials) found that HbA1c rose by a mean of 0.19% after 12 months of GH therapy [8]. MOTS-c's insulin-sensitizing mechanism could theoretically blunt this GH-associated glucose dysregulation, making the stack metabolically safer than ipamorelin alone at higher doses. This hypothesis has not been tested in a controlled human trial.

Body Composition Rationale

Ipamorelin drives lipolysis and lean tissue preservation via IGF-1. MOTS-c enhances mitochondrial oxidative capacity and may increase the proportion of fatty acids burned rather than stored. The combination could, in theory, accelerate fat loss while preserving muscle more effectively than either agent alone. Animal data support this directionally: mice receiving both GH-pathway activation and AMPK stimulation show superior body composition outcomes compared with single-agent arms [9].

Who Might Benefit Most

Adults over 35 with documented IGF-1 below 150 ng/mL, HOMA-IR above 2.0, or metabolic syndrome criteria per the 2009 joint scientific statement (waist circumference, triglycerides, HDL, blood pressure, fasting glucose thresholds) may show the clearest measurable response [10]. Lean, young athletes without metabolic dysfunction have less physiologic justification and more theoretical risk from GH-axis manipulation.

Complete Dosing Protocol

No published RCT defines the optimal dose or schedule for this combination. The following protocol synthesizes animal pharmacokinetics, practitioner-reported clinical observations, and the pharmacology of each agent individually.

Ipamorelin Dosing

• Starting dose: 100 mcg subcutaneous injection, once daily at bedtime.
• Titration: After 2 weeks, increase to 200 mcg if IGF-1 has not reached the mid-normal range for age and sex (typically 100 to 250 ng/mL in adults 30 to 50).
• Maximum dose: 300 mcg per injection. Some practitioners use split dosing (150 mcg morning, 150 mcg bedtime), but the evidence base for split dosing over single bedtime dosing is anecdotal.
• Timing: Administer at least 2 hours after the last meal. Insulin spikes blunt GH release via somatostatin; fasted administration preserves the GH pulse [11].
• Reconstitution: Standard bacteriostatic water, 2 mL per 5 mg vial, yielding 2,500 mcg/mL. Draw 0.04 mL (40 units on an insulin syringe) for a 100 mcg dose.

MOTS-c Dosing

• Starting dose: 5 mg subcutaneous injection, 3 times per week (Monday, Wednesday, Friday).
• Maintenance dose: 10 mg 2 to 3 times per week after 4 weeks if the patient tolerates the starting dose without injection-site reactions.
• Timing: Morning administration on workout days appears consistent with the exercise-mimicry mechanism. Inject 30 to 60 minutes before training when possible.
• Reconstitution: Bacteriostatic water, 1 mL per 10 mg vial, yielding 10,000 mcg/mL. Draw 0.5 mL for a 5 mg dose.

Injection Sites

Both peptides are administered subcutaneously. Rotate sites among abdomen, lateral thigh, and lateral upper arm. Avoid the same site on consecutive days. Use 29 to 31 gauge, 0.5-inch insulin syringes for both.

Cycling Protocol

Recommended Cycle Structure

A standard approach used in clinical observation settings:

• Weeks 1 to 8: Full dose ipamorelin nightly + MOTS-c 3x weekly.
• Weeks 9 to 12: Option A (continue at full dose if IGF-1 and glucose markers are within targets). Option B (taper ipamorelin to 5 days/week to reduce cumulative GH-axis stimulation).
• Weeks 13 to 20: Off-cycle. Allow the GH axis to return to baseline. Measure IGF-1 at week 16 to confirm washout.
• Repeat cycle: Reassess metabolic markers before starting a second cycle.

Why Cycle at All

Continuous GH-axis stimulation can downregulate GHS-R1a receptors and suppress endogenous GH pulsatility. Animal data show receptor desensitization with daily GHRP administration over 12 weeks [12]. Cycling preserves receptor sensitivity and avoids the prolonged IGF-1 elevation that has been associated with acromegaly-related comorbidities at pharmacologic (not physiologic) doses.

Monitoring and Safety

Baseline Labs

Order before starting any GH secretagogue or mitochondrial peptide:

• IGF-1 (ng/mL, age- and sex-referenced)
• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c
• Comprehensive metabolic panel (CMP)
• Lipid panel
• Thyroid-stimulating hormone (TSH)
• Sex hormones (testosterone total/free, estradiol, SHBG) if concurrent TRT or HRT

On-Cycle Monitoring

Repeat IGF-1 and fasting glucose at week 4 and week 8. If IGF-1 exceeds the upper limit of the age-adjusted normal range (roughly 250 to 300 ng/mL in adults under 50, per Endocrine Society GH deficiency guidelines) [3], reduce the ipamorelin dose by 50 mcg. If fasting glucose rises above 100 mg/dL from a normal baseline, reassess MOTS-c timing and consider adding berberine 500 mg twice daily as a concurrent insulin sensitizer.

Known Adverse Effects of Ipamorelin

At doses up to 300 mcg/day, ipamorelin's adverse effect profile is mild. Common reports include transient water retention (edema, especially periorbital and hand) in the first 2 weeks, mild tingling or numbness (carpal tunnel-like symptoms from rapid fluid shifts), and occasional injection-site erythema. These effects are dose-dependent and typically resolve with dose reduction [1].

Known Adverse Effects of MOTS-c

Human safety data are limited. Mouse studies using 15 mg/kg showed no organ toxicity over 8 weeks [4]. In practitioner-reported human use at 5 to 10 mg doses, adverse effects include transient injection-site discomfort and, rarely, mild fatigue on dosing days. Hypoglycemia has not been reported at these doses but remains a theoretical concern given AMPK activation and improved insulin sensitivity, particularly in patients already on insulin secretagogues or SGLT2 inhibitors.

Drug Interactions

MOTS-c potentiates insulin sensitivity. Patients on metformin, sulfonylureas, GLP-1 receptor agonists (semaglutide, tirzepatide), or SGLT2 inhibitors should have glucose monitoring intensified during the first 4 weeks. Ipamorelin has no known pharmacokinetic interactions with common medications but should be used with caution alongside glucocorticoids, which blunt GH release via somatostatin upregulation [11].

Evidence Summary: What the Data Actually Show

What Is Established

Ipamorelin raises GH pulse amplitude and IGF-1 in a dose-dependent fashion. This is supported by receptor pharmacology data [1] and by clinical analogy to other GHS-R1a agonists studied in GH-deficient populations [3]. MOTS-c improves insulin sensitivity and prevents diet-induced obesity in rodents [4], and human observational data show an inverse correlation between plasma MOTS-c and metabolic disease markers [6].

What Is Extrapolated

The combination has no human RCT. Body composition benefits from stacking a GH secretagogue with an AMPK activator are mechanistically plausible and directionally supported by animal co-administration data [9], but effect sizes in humans are unknown.

What Is Unknown

Optimal human dose for MOTS-c is not established. Long-term safety beyond 12 weeks in humans is not documented. The degree to which exogenous MOTS-c blunts GH-induced glucose dysregulation is speculative. Practitioners and patients must weigh this evidence gap explicitly before initiating the stack.

As the Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency notes, "GH therapy should be used to achieve serum IGF-1 concentrations within the age-appropriate reference range, and doses should be titrated based on clinical response and IGF-1 levels rather than weight-based algorithms" [3]. This principle applies equally to GH secretagogues used off-label.

Practical Stack Schedule: Week-by-Week Overview

| Week | Ipamorelin | MOTS-c | Labs | |------|-----------|--------|------| | 0 (baseline) | None | None | Full panel | | 1 to 2 | 100 mcg nightly | 5 mg 3x/week | None | | 3 to 4 | 200 mcg nightly | 5 mg 3x/week | Fasting glucose | | 5 to 8 | 200 to 300 mcg nightly | 10 mg 3x/week | IGF-1, glucose at week 8 | | 9 to 12 | 200 to 300 mcg nightly or 5x/week | 10 mg 2x/week | IGF-1 at week 12 | | 13 to 20 | Off | Off | IGF-1 at week 16 |

Sourcing and Legal Considerations

Neither ipamorelin nor MOTS-c is FDA-approved for human use outside of research contexts. Ipamorelin is not on the FDA's current list of approved drug products (Orange Book) [13]. MOTS-c has no IND (Investigational New Drug) application on record for commercial use. Both are sold as research chemicals. The FDA issued guidance in 2023 restricting compounding pharmacies from producing certain peptides, including some GHRPs, under 503A and 503B regulations [14]. Patients should confirm the regulatory status of any peptide with their prescribing physician and source only from licensed compounding pharmacies with USP 797 compliance.

The World Anti-Doping Agency (WADA) prohibits GH secretagogues including GHS-R1a agonists under Section 2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the Prohibited List. Athletes subject to drug testing must not use ipamorelin [15].